{"id":9483,"date":"2024-09-13T00:03:07","date_gmt":"2024-09-13T00:03:07","guid":{"rendered":"https:\/\/businesstriumphs.com\/index.php\/2024\/09\/13\/the-sctr-report-insmeds-stock-hangs-in-the-balance-heres-what-you-need-to-know\/"},"modified":"2024-09-13T00:03:07","modified_gmt":"2024-09-13T00:03:07","slug":"the-sctr-report-insmeds-stock-hangs-in-the-balance-heres-what-you-need-to-know","status":"publish","type":"post","link":"https:\/\/businesstriumphs.com\/index.php\/2024\/09\/13\/the-sctr-report-insmeds-stock-hangs-in-the-balance-heres-what-you-need-to-know\/","title":{"rendered":"The SCTR Report: Insmed\u2019s Stock Hangs in the Balance\u2014Here\u2019s What You Need to Know"},"content":{"rendered":"
\n

Numerous companies are making strides within their respective sectors, but, unless you follow the sector closely, you might not be aware of them. That\u2019s what makes StockCharts Technical Rank<\/a> (SCTR) reports so helpful.<\/span><\/p>\n

If you\u2019ve checked your SCTR reports regularly, you might have noticed Insmed<\/strong> (INSM) appear at or near the top over the last three months.<\/p>\n

FIGURE 1. DAILY SCTR REPORTS SHOW INSM IN THE OF THE TOP-UP, LARGE-CAP STOCKS.<\/span>Image source: StockCharts.com. For educational purposes.<\/span><\/em><\/p>\n

Insmed (INSM) is a biotech company that has had a near-perfect SCTR score of 99.9 since the end of May.<\/p>\n

A SCTR (pronounced scooter<\/em>) score above 90 is exceedingly bullish, as it signals technical strength across multiple technical indicators and timeframes. Sustaining a score well above 90 for months tells you that something tremendous is happening with the company and its stock.<\/p>\n

But if you don\u2019t follow biotech, you\u2019re probably wondering, \u201cWhat is Insmed? Why haven\u2019t I heard of it? Why is it soaring now? Where was it before it showed up on the SCTR report\u2019s top spot?\u201d<\/p>\n

In a Nutshell, Here\u2019s What\u2019s Driving INSM<\/h2>\n

Insmed\u2019s stock is popping thanks to positive results from a late-stage study of its antibiotic drug Arikayce, developed for treating a rare, severe lung infection. The study\u2019s success boosts hopes for broader FDA approval, driving INSM\u2019s sharp breakaway gap<\/a> to all-time highs.<\/span><\/p>\n

Before this, however, what did INSM\u2019s performance look like?<\/p>\n

Three-Year Lookback at INSM\u2019s Performance<\/h2>\n<\/p>\n

FIGURE 2. WEEKLY CHART OF INSM. The recent tests catapulted INSM to all-time highs.<\/span>Chart source: StockCharts.com. For educational purposes.<\/span><\/em><\/p>\n

Take note of the following points:<\/p>\n

The breakaway gap (see orange short-term downsloping trend line) from $22 to $49.53 marked a 125% spike.
\nWhile INSM\u2019s SCTR score has exceeded the 90 line four times in the last three years (see green circles), notice how it barely outperformed, and largely underperformed, its broader industry, represented by the Dow Jones U.S. Biotechnology Index<\/strong> ($DJUSBT).
\nThe latest break above the 90 line looks flat-out bullish (see green rectangle), aligning with a 171% outperformance of its industry.<\/p>\n

Does this make INSM a strong candidate for a long position? To explore that further, let\u2019s shift to a daily chart<\/a>.<\/span><\/p>\n

Should You Go Long INSM?<\/h2>\n<\/p>\n

FIGURE 3. DAILY CHART OF INSM. Note the declining momentum and topping formation.<\/span>Chart source: StockCharts.com. For educational purposes.<\/span><\/em><\/p>\n

Here are the main things to keep an eye on:<\/p>\n

INSM looks to be forming a double top<\/a>; still, market sentiment reacting to INSM\u2019s latest testing news and developments moving forth may defy (bearish) technical indications.<\/span>
\nThe Chaikin Money Flow<\/a> (CMF) shows that buying pressure is fading, matching up with the <\/span>Relative Strength Index\u2019s<\/a> (RSI\u2019s) bearish divergence signal from overbought levels.<\/span>
\nDespite looking toppy, for INSM\u2019s near-term uptrend to continue, you\u2019d want to see it break above resistance at its all-time level of $80.53 while remaining above its most recent swing low at the $70 range.
\nIf it falls below the $70 range, the next lines of support can be at the previous swing lows of $67.20 and $61.50.<\/p>\n

Warning: A deeper correction may indicate that something is off between the technical reading and the market\u2019s reaction to the company\u2019s news or product development.<\/em><\/strong><\/p>\n

If INSM falls below $61.50, the long-term uptrend could still hold despite invalidating the short-term trend. Be extra careful, though! INSM might slide to $45\u2013$52, hitting key Fibonacci retracement levels<\/a>, but a dip that low could mean something big has changed with INSM\u2019s product development, and the price action may be reflecting the market\u2019s response to these (bearish) developments<\/em>.<\/p>\n

Closing Bell<\/h2>\n

StockCharts\u2019 SCTR Reports spotlight hidden stock opportunities that might not have crossed your radar. Insmed is a great example. It\u2019s been riding high on positive testing news, but its technicals are flashing warning signs. If you want to follow INSM\u2019s price action, add it to one of your StockCharts ChartLists<\/a>. If not, be sure to use SCTR daily to find other (potentially hidden) opportunities for your next trade.<\/span><\/p>\n

Disclaimer: <\/em><\/strong>This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Numerous companies are making strides within their respective sectors, but, unless you follow the sector closely, you might not be aware of them. That\u2019s what makes StockCharts Technical Rank (SCTR) reports so helpful. If you\u2019ve checked your SCTR reports regularly, you might have noticed Insmed (INSM) appear at or near the top over the last […]<\/p>\n","protected":false},"author":0,"featured_media":9484,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-9483","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock"],"_links":{"self":[{"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/posts\/9483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/comments?post=9483"}],"version-history":[{"count":0,"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/posts\/9483\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/media\/9484"}],"wp:attachment":[{"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/media?parent=9483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/categories?post=9483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/tags?post=9483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}